FDA Proposes New Registration, Listing Rules for Distributed Manufacturing
Drug manufacturers using distributed or foreign production must prepare for new FDA registration and listing requirements under a July 2026 proposed rule.
On July 13, 2026, FDA published a proposed rule overhauling drug establishment registration and drug listing requirements for distributed manufacturing (DM) sites and foreign establishments. The rule creates a dedicated registration and listing pathway for DM arrangements, where multiple sites contribute to a single finished drug product, and aligns foreign establishment obligations with current statutory requirements. Key impacts include new identification and listing obligations for each DM site, potential changes to U.S. agent designations, and updated expectations for cross-border supply chains. Manufacturers operating DM networks or relying on foreign production should evaluate site-level registration gaps, update listing data, and prepare comments before the comment period closes. Early compliance planning will be critical to avoid misbranding or registration lapses once the rule is finalized.